Because AKR1C3 overexpression is associated with drug resistance in prostate and breast cancers [13,15], we hypothesized that suppression of AKR1C3 activity would increase the sensitivity of HCC cells to sorafenib. The gene discussed is AKR1C3; the disease is hepatocellular carcinoma.